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Background: Rapid diagnosis of Plasmodium falciparum infections is important because of the potentially fatal
complications. SDFK90 is a recently marketed malaria rapid diagnostic test (RDT) targeting both histidine-rich
protein 2 (PfHRP2) and P. falciparum-specific Plasmodium lactate dehydrogenase (Pf-pLDH). The present study
evaluated its diagnostic accuracy.
Methods: SDFK90 was tested against a panel of stored whole blood samples (n= 591) obtained from international
travellers suspected of malaria, including the four human Plasmodium species and Plasmodium negative samples.
Microscopy was used as a reference method, corrected by PCR for species diagnosis. In addition, SDFK90 was
challenged against 59 P. falciparum samples with parasite density ≥4% to assess the prozone effect (no or weak
visible line on initial testing and a higher intensity upon 10-fold dilution).
Results: Overall sensitivity for the detection of P. falciparum was 98.5% and reached 99.3% at parasite densities
>100/μl. There were significantly more PfHRP2 lines visible compared to Pf-pLDH (97.3% vs 86.9%), which was
mainly absent at parasite densities <100/μl. Specificity of SDFK90 was 98.8%. No lot-to-lot variability was observed
(p = 1.00) and test results were reproducible. A prozone effect was seen for the PfHRP2 line in 14/59 (23.7%) P.
falciparum samples tested, but not for the Pf-pLDH line. Few minor shortcomings were observed in the kit’s
packaging and information insert.
Conclusions: SDFK90 performed excellent for P. falciparum diagnosis. The combination of PfHRP2 and Pf-pLDH
ensures a low detection threshold and counters potential problems of PfHRP2 detection such as gene deletions
and the prozone effect.
Keywords: Malaria, Plasmodium falciparum, Diagnosis, Rapid diagnostic test, Histidine-rich protein, Plasmodium
falciparum-specific Plasmodium lactate dehydrogenase, EvaluationBackground
Plasmodium falciparum is the most dangerous malaria
species in both endemic and non-endemic settings as it
can easily lead to severe complications and death. There-
fore rapid diagnosis and treatment are crucial to reduce
morbidity and mortality [1]. Although microscopy is the
cornerstone of malaria diagnosis, it requires special equip-
ment and expertise, which is often unavailable in both en-
demic and non-endemic settings. Malaria rapid diagnostic
tests (RDTs) are hand-held cassettes containing a nitrocel-
lulose membrane on which detection of Plasmodium* Correspondence: jmaltha@itg.be
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distribution, and reproduction in any mediumantigens become visible as blue or cherry-red lines. Two
detection antigens exist for P. falciparum diagnosis:
histidine-rich protein-2 (PfHRP2) and P. falciparum-
specific Plasmodium lactate dehydrogenase (Pf-pLDH).
PfHRP2 is the most frequently used detection antigen and
it is known to have a lower detection limit compared to
Pf-pLDH [2]. However, Pf-pLDH also has advantages over
PfHRP2: it is not affected by the prozone effect [3,4] nor
by pfhrp2 gene deletions [5]. Therefore, a RDT product
detecting both PfHRP2 and Pf-pLDH could be of particu-
lar interest as the disadvantages of one detection antigen
may be countered by the other. The recently marketed
RDT product SD Malaria Antigen P.f 05FK90-02-0
(HRP2/pLDH), Standard Diagnostics, Inc., Kyonggi-do,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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RDTconsisting of a control line, a test line with antibodies
directed to PfHRP2 and a different test line with anti-
bodies directed to Pf-pLDH. The present study evaluated
the diagnostic accuracy of SDFK90 in a non-endemic
setting.Methods
Study design
The SDFK90 was evaluated using a panel of stored blood
samples in a non-endemic reference laboratory. All sam-
ples were obtained from international travellers suspected
of malaria. The reference method was microscopy cor-
rected by polymerase chain reaction (PCR) for Plasmodium
detection and species identification. Microscopy was used
to determine parasite densities and stages. The study de-
sign was in compliance with the STARD guidelines for
presentation of diagnostic studies [6].Patients and materials
The evaluation panel was selected from EDTA anti-
coagulated whole blood samples. The majority of samples
were obtained from patients presenting at the outpatient
clinic of the Institute of Tropical Medicine (ITM) in Ant-
werp, Belgium. An additional part was submitted to ITM
by other Belgian laboratories for confirmation in the scope
of the national reference laboratory for the diagnosis of
malaria. The samples were obtained from international
travellers suspected of malaria. Samples were obtained be-
tween February 1996 and May 2011. Samples collected at
ITM were kept at room temperature, below 25°C, for a
maximum of eight hours before being stored at −70°C.
Samples acquired from other Belgian laboratories had
been exposed to ambient temperatures for the period of
shipment which was generally less than 24 hours with a
maximum of 48 hours. The selected panel comprised the
four human Plasmodium species at different parasite
densities, as well as Plasmodium negative samples con-
firmed by microscopy, PCR and RDTs used in standard
diagnostic work-up. The selected panel also included five
samples that showed a prozone effect in a previous ITM
study [3]. Samples with pure gametocytaemia were
included among the P. falciparum species. Mixed infec-
tions were not considered.
Additionally, samples obtained from patients present-
ing at the Provincial Hospital of Tete (Mozambique)
which had shown a prozone effect in a previous ITM
study [4] were used to assess the prozone effect: samples
with high parasite densities (≥4%) having no visible, faint
or weak test lines and a higher line intensity when tested
with a 10-fold dilution [3]. The samples were stored
at −70°C for 15–21 months.Reference method
Malaria diagnosis at ITM is accredited to the require-
ments of ISO 15189:2007. An expert microscopist
assessed all samples for the presence of Plasmodium
parasites. Species identification and parasite density
were performed according to the WHO standards for
microscopy. The only exception was that Giemsa stain-
ing was done with pH 8.0 [7,8]. Thick and thin blood
films were prepared and examined by light microscopy.
A minimum of 200 fields were examined before a blood
film was reported negative. The parasite density was
obtained by counting the asexual parasites against 200
or 500 white blood cells (WBC) in thick blood films
and using the WBC count or, when not available, the
standard 8,000 WBC/μl, for the conversion to parasites/
μl [7,8]. Four-primer real-time PCR was performed on
all samples [9]. The result of microscopy corrected by
PCR was considered for species identification. PCR
results were used for final species identification; micros-
copy was used for stage determination (especially game-
tocytes for P. falciparum) and determination of parasite
density.Test platforms
SDFK90 consists of a control line and two test lines:
Pf-pLDH and PfHRP2. The test is considered positive
for P. falciparum when the control line is present and
one or both test lines. In case of absence of the control
line the test was considered invalid and repeated. Kits
from two different lot numbers were used: MFRDT1001
(n = 234) and MFRDT1002 (n = 416). RDTs had been
stored between 18°C and 24°C.Test procedures
Tests were carried out in time-controlled batches and
in compliance with the instructions of the manufac-
turer, except for replacement of the included plastic
transfer devices by a transfer pipette (Finnpipette,
Helsinki, Finland). Readings were carried out at
daylight assisted by a standard light source. Readings
were subsequently carried out by three trained obser-
vers the first two of whom performed the RDTs. All
three observers scored test results within the recom-
mended reading time (15–30 minutes). Photographs of
the batches were taken within 15–30 minutes. The
observers were blinded to microscopy, PCR and each
other’s results.
A scoring system was used to categorize line inten-
sities: negative, faint, weak, medium and strong [10].
Test results were based on consensus, i.e. an identical
score by at least two out of three readers. In case of dis-
cordances and absence of consensus, the photographs
were reviewed to conclude.
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Data was recorded on register forms and entered in
a Microsoft Excel database (Microsoft Corporation,
Redmond, Washington, USA). End points were sensitiv-
ity, specificity, inter-observer agreement and reproduci-
bility. Sensitivity and specificity were calculated with
95% confidence interval (CI). Proportions were assessed
for statistical significance using the two-tailed Fisher’s
exact test and the McNemar test, for unpaired and
paired panels respectively. A p-value < 0.05 was consid-
ered significant.
Inter-observer agreement for both positive and nega-
tive readings as well as for line intensity was expressed
by the percentage of overall agreement and by kappa
values for each pair of observers. A Kappa value of 0.6-
0.8 was considered good, > 0.8 was considered excellent
[11]. Test reproducibility was evaluated by testing 15
samples representing all species at varying parasite dens-
ities on six occasions.
Additional analysis
PfHRP2 antigen qualitative ELISA (SD Malaria Antigen
P.f ELISA, Standard Diagnostics, Inc., Kyonggi-do,
Korea) was performed in case of a visible PfHRP2 line
among Plasmodium negative samples or non-falciparum
infections, to determine the presence of circulation
PfHRP2 antigen. All false negative P. falciparum samples
and non-falciparum samples that generated a PfHRP2
and/or Pf-pLDH line were retested with the SDFK90.
Assessment of the prozone effect
PfHRP2 RDTs may be affected by the prozone effect, a
false-negative or false-low result due to an excess of
antigens [3]. To assess the susceptibility of SDFK90
for the prozone effect, samples with high parasitaemia
(n = 59, parasite density ≥ 4%) that showed a prozone ef-
fect in previous ITM studies were assessed with SDFK90
side-to-side with two PfHRP2-detecting RDTs, Para-
check Pf (PfHRP2, Orchid Biomedical Systems, Goa,
India, lot number 31797) and ICT Pf (PfHRP2, ICT
Diagnostics, Cape Town, South Africa, lot numbers
50045 and 32784). Whole blood samples were tested as
well as a 10x dilution with NaCl 0.9%. RDTs were per-
formed as described above, except that the reading was
done by two, instead of three, observers. A prozone ef-
fect was defined as a sample with a negative, faint or
weak test line when tested undiluted, and a visible test
line of higher intensity at 10-fold dilution, as observed
by two blinded observers [4].
Package, labelling and instructions for use
Checklist for assessing quality of packaging, labelling
and instructions were applied [12]. The Flesh Kincaid
Grade Level was used to score the readability of themanufacturer’s instructions: it indicates the number of
years of education that is needed to understand the text,
based on measures of word and sentences length [12]. In
addition, letter type (open versus closed), font size, and
inter-line spacing were assessed as previously described
[12].
Ethical review
The study was approved by the Institutional Review




The collection consisted of 591 samples obtained in 591
patients with a median age of 36 years (range five
months to 85 years), and a male to female ratio of 1.7:1.
Eight children (1.4%) under the age of five were
included. In 492 (83.2%) patients the travel history was
known, 86.6% (426/492) of them had recently returned
from Sub-Saharan Africa and 9.1% (45/492) from Asia.
The samples included 336 P. falciparum, 72 Plasmodium
vivax, 71 Plasmodium ovale and 16 Plasmodium malariae
samples. Microscopic species identification was corrected
by PCR in seven out of the 495 positive samples (1.4%).
This correction only comprised P. vivax - P. ovale mis-
matches: in the final collection, two out of 72 (2.8%) P.
vivax samples and five out of 71 (7.0%) P. ovale samples
had been identified respectively as P. ovale and P. vivax by
microscopy. Among the P. falciparum samples, there were
18 with pure gametocytaemia as identified by microscopy.
The median parasite density of the remaining 318 P. fal-
ciparum samples was 4,876.5/μl (range 6–1,750,000/μl).
The median (range) parasite densities for P. vivax, P. ovale
and P. malariae were 1,834/μl (15–32,000/μl), 609/μl
(10–10,000/μl), and 473/μl (0.1–6,096/μl) respectively. In
addition, 96 microscopic and PCR malaria negative sam-
ples of symptomatic travellers were included in the panel.
The sample collection for assessment of the prozone
effect consisted of 59 P. falciparum samples mainly
obtained in malaria suspected patients in Mozambique
(n=54) and at ITM (n=5). The parasite density ranged
from 200,000–1,750,000 parasite/μl (median 460,000).
The median age of these patients was three years (range
three months to 73 years), 69.5% (41/59) was <5 years of
age. The male to female ratio was 0.97:1.
Test characteristics
No invalid test results were obtained. The majority of
the P. falciparum samples (288/336, 85.7%) showed both
PfHRP2 and Pf-pLDH test lines (Table 1). Of the five P.
falciparum samples not detected by SDFK90, two had
pure gametocytaemia, the other three had parasite dens-
ities of 83/μl, 703/μl and 2,043/μl.
Table 1 Test results of SDFK90 for all samples (n = 591), except for samples assessed for the prozone effect
PfHRP2 line positive PfHRP2 line negative
Pf-pLDH line positive Pf-pLDH line negative Pf-pLDH line positive Pf-pLDH line negative
P. falciparum (n = 336) 288 39* 4† 5‡
P. vivax (n = 72) 1§ 2§ 69
P. ovale (n = 71) 71
P. malariae (n = 16) 16
Negative (n = 96) 96
* five samples with pure gametocytaemia, other samples parasite density: 6/μl–2,622/μl (median 71/μl).
† two samples with pure gametocytaemia, other samples parasite density: 238/μl, 1,123/μl.
‡ two pure gametocytaemia, other samples parasite density 83/μl, 703/μl, 2,043/μl.
§ Species mismatch.
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the two test lines combined was 98.5% and increased to
99.3% at parasite densities >100/μl (Table 2). Overall sensi-
tivity for the PfHRP2 test line (97.3%) was significantly
higher compared to that of the Pf-pLDH test line (86.9%,
p = 0.0001). When the samples with pure gametocytaemia
were subtracted it was clear that this difference was
mainly caused by differences in sensitivity at parasite dens-
ities below 100/μl (Table 3). There was no difference (p =
1.00) in diagnostic sensitivity between the two lots tested.
Three out of the 72 P. vivax samples (parasite densities
of 568/μl, 916/μl and 3,875/μl) showed a visible PfHRP2
test line and one of them showed an additional Pf-pLDH
line. These three samples showed also strong positive
results in the PfHRP2 qualitative antigen ELISA. None of
the Plasmodium negative, P. ovale and P. malariae sam-
ples showed a visible test line (Tables 1 and 2).
Intensity of test lines
Among P. falciparum samples, the majority (283/327,
86.5%) of visible PfHRP2 test lines had medium orTable 2 Sensitivity and specificity of SDFK90 for the detection
Microscopy corrected by PCR Number
All P. falciparum samples 336
Pure gametocytaemia 18
Asexual parasite density 1-100/μl 36
Asexual parasite density 101-200/μl 19
Asexual parasite density 201-1,000/μl 44
Asexual parasite density >1,000/μl 219
Asexual parasite density >100/μl 282
Excluding pure gametocytaemia 318
All other species and no parasites detected 255
No parasites detected 96
P. vivax 72
P. ovale 71
P. malariae 16strong line intensities. For the Pf-pLDH line, only 45.5%
(133/292) of test lines had medium or strong line inten-
sities (p = 0.0001), all but two occurred among samples
with parasite densities higher than 1,000/μl. In addition,
3.7% of the correctly identified PfHRP2 test lines had
faint line intensity, whereas this was 17.8% for the Pf-
pLDH line.
Inter-observer agreement and reproducibility
For both PfHRP2 and Pf-pLDH test lines overall agree-
ment (≥ 98.8%) and kappa values between pairs of obser-
vers (≥ 0.97) were excellent for positive and negative
readings. For line intensity readings kappa values were
good and excellent (0.75–0.92). Consensus in line inten-
sity reading was obtained for all cases, except for three
samples and only for the Pf-pLDH line with as respect-
ive results for the three observers: faint, negative and
weak). After review of the photographs, the faint test
line intensity was used as consensus. Test results were
reproducible and all discordances in line intensity oc-





















Table 3 Sensitivities of both test lines separately for the detection of Plasmodium falciparum






All P. falciparum samples 336 97.3 (95.0-98.8) 86.9 (82.8-90.3) 0.0001
Pure gametocytaemia 18 77.8 (52.4-93.6) 61.1 (35.8-82.7) 0.4497
Asexual parasite density 1-100/μl 36 97.2 (85.5-99.9) 30.6 (16.4-48.1) 0.0001
Asexual parasite density 101-200/μl 19 100 (82.4-100) 73.7 (48.8-90.9) 0.0736
Asexual parasite density 201-1,000/μl 44 95.5 (84.5-99.4) 88.6 (75.4-96.2) 0.3711
Asexual parasite density >1,000/μl 219 99.1 (96.7-99.9) 99.1 (96.7-99.9) 0.4795
Asexual parasite density >100/μl 282 98.6 (96.4-99.6) 95.7 (92.7-97.8) 0.0433
Excluding pure gametocytaemia 318 98.4 (96.4-99.5) 99.1 (97.3-99.8) 0.4658
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false negative P. falciparum samples as well as the three
P. vivax samples with PfHRP2 and/or Pf-pLDH lines
scored identical to initial testing.
Assessment of the prozone effect
A prozone effect was seen in the PfHRP2 test line of 14/
59 (23.7%) samples tested by SDFK90; all 14 samples
generated weak test lines whereas they showed strong
line intensities upon 10-fold dilution. The prozone effect
was not observed for the Pf-pLDH test line. Paracheck
and ICT Malaria Pf showed a prozone effect in 15/58
(25.9%) and 31/58 (53.4%) of samples respectively.
Package, labelling and instructions for use
The following shortcoming were noted: the SDFK90 kit’s
box and labels were not humidity resistant and the
names as displayed on information inserts, boxes, the
device blisters and buffer vials showed slight differences.
The plastic housing of the cassette however was clearly
labelled and specified target antigens by their names.
The instructions for use did not mention: (i) do not
store the test in a freezer, (ii) check the saturation of sil-
ica gel, (iii) write the patient’s identification on the cas-
sette; and, (iv) use only the buffer vial provided in the
kit. Readability expressed as Flesh Kincaid Grade Level
was 11.02, an open letter type was used and font size
was 7 with an interline spacing of 1.
Discussion
The present study assessed the performance of SDFK90
for malaria diagnosis, a RDT detecting both PfHRP2 and
Pf-pLDH, using stored samples obtained in international
travellers suspected of malaria. Overall sensitivity for P.
falciparum was 98.5% and reached 99.3% at parasite
densities above 100/μl. Specificity for non-falciparum
and Plasmodium negative samples was 98.8%.
A number of limitations need to be considered. Due to
the use of stored samples, clinical information poten-
tially explaining false positive or false negative results,such as the visible PfHRP2 line among three P. vivax
samples, was not available. Furthermore, because of the
use of stored (lysed) blood samples, a calibrated pipette
was used instead of the RDT kit’s original transfer device
(“loop”). This could bypass possible errors in transfer
volume, which may occur when performing the test in a
field setting. Finally, the application of stringent inter-
pretation criteria unfavourably influenced test outcomes:
P. falciparum samples with pure gametocytaemia were
included among the positive samples. Although mean-
ingful in the scope of travel medicine [13], it added to
the false-negative results and decreased the sensitivity of
SDFK90.
SDFK90 was previously evaluated in the third evalu-
ation round of the World Health Organization (WHO)
and the Foundation for Innovative New Diagnostics
(FIND) [14], in which detection of P. falciparum and P.
vivax was assessed using diluted samples at fixed para-
site densities. The detection rate for P. falciparum was
87.9% and 100% at low (200/μl) and high (2,000/μl or
5,000/μl) parasite densities respectively. In the present
study, even at parasite densities <200/μl sensitivity
already reached 97.2%.
PfHRP2 detection has advantages over the use of Pf-
pLDH antigen detection. That is, PfHRP2-detecting RDTs
are generally reported to be more heat resistant, although
some Pf-pLDH-detecting RDTs do have extended
temperature stabilities [11,14]. The heat stability testing
of the WHO/FIND study confirmed resistance of the
SDFK90 to temperatures up to 45°C [11,14-16]. More-
over, PfHRP2-detecting RDTs are generally reported to
have lower sensitivity for P. falciparum diagnosis, espe-
cially at parasite densities ≤100/μl [2,11,17-19].
On the other hand, detection of the Pf-pLDH antigen
also has some advantages over PfHRP2 detection [11].
Unlike the PfHRP2 antigen, Pf-pLDH is not susceptible
to the prozone effect, i. e., a missed or delayed diagnosis
at high parasite densities, as was confirmed in the
present study. Although rare in travel medicine, the con-
sequences of prozone can lead to serious complications
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alone for diagnosis [3,20]. The detection of both Pf-
pLDH and PfHRP2 will offer a back-up in case of a pro-
zone effect. In addition, it will offer a back-up in sam-
ples lacking the pfhrp2 gene [5]: 25.7%–41.0% of P.
falciparum samples in the Peruvian Amazon lack the
pfhrp2 gene which encodes PfHRP2 [5,21]. All PfHRP2-
detecting RDTs evaluated by Maltha et al. failed to cor-
rectly diagnose these samples, whereas SDFK90, like the
Pf-pLDH-detecting RDTs, correctly identified the P.
falciparum infections because of the presence of the Pf-
pLDH test line [5].
PfHRP2 is produced by asexual parasites and young
gametocytes. It is expressed on the red blood cell mem-
brane and readily diffuses in the plasma. Due to its slow
clearance, PfHRP2 antigen persists in the bloodstream
for up to several weeks after successful treatment of the
infection [22-24]. Pf-pLDH is an enzyme of the
glycolytic pathway produced by asexual stages and
gametocytes and its presence depends on living para-
sites. Pf-pLDH quickly disappears from the blood when
parasites have been cleared [2,25].
Although the Pf-pLDH antigen is rapidly cleared from
the blood once treatment is initiated [22-24], its use for
treatment follow-up has been abandoned because of the
persistence of gametocytes for up to two weeks after the
start of the treatment [26,27]. On the other hand,
artemisinin-based combination therapy results in low
post-treatment gametocytaemia with Pf-pLDH antigen
levels below the RDT detection threshold [28]. While
the use of Pf-pLDH to follow-up treatment and detec-
tion of therapy resistance is still under debate and await-
ing further study, it can be argued that the combination
of PfHRP2 and Pf-pLDH in the SDFK90 could offer an
opportunity for treatment follow-up.
As expected, the specificity of the Pf-pLDH line was
higher compared to the PfHRP2 line [17]. This can be
explained by the persistence of PfHRP2 antigen for up
to several weeks after successful treatment. Due to the
retrospective design of this study, clinical information
explaining the reactions of the PfHRP2 line with three P.
vivax samples was not available, but the identical posi-
tive result in PfHRP2 ELISA suggests PfHRP2 persist-
ence after a previous P. falciparum infection.
Line intensities of Pf-pLDH were lower than those of
PfHRP2, irrespective of parasite densities. In previous
studies, the ITM team consistently found lower line in-
tensities in pLDH test lines [10,11,29-33]. In particular
weak and faint line intensities are of concern, as they
tend to be regarded as negative [34]. The observed
shortcomings in instructions for the use and labelling of
the kit’s package and contents were in line with observa-
tions made for other RDT kits [12] and can easily be
corrected.Conclusion
SDFK90 performed excellently for the diagnosis of P.
falciparum. The detection of both PfHRP2 and Pf-pLDH
ensures a low detection threshold and minimizes poten-
tial problems of PfHRP2 detection such as gene dele-
tions and the prozone effect. Further evaluation of
SDFK90 in an endemic setting is needed to determine
predictive values and its possible use for treatment fol-
low-up.
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